Phase I dose-escalation trial investigating the safety and tolerability of EP0906 plus estramustine in patients with advanced cancer.

被引：0
|
作者：
Wojtowicz, M
Rothermel, JD
Anderson, J
Todd, M
Rubin, EH
Dipaola, RS
机构：
[1] Canc Inst New Jersey, New Brunswick, NJ USA
[2] Novartis Pharmaceut Corp, E Hanover, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4623
引用
收藏
页码：412S / 412S
页数：1
相关论文
共 50 条
  • [21] Phase I dose-escalation trial evaluating the safety and pharmacokinetics of sorafenib combined with capecitabine in patients with advanced solid tumors
    Awada, A.
    Gil, T.
    Whenham, N.
    Vanhamme, J.
    Mancini, I.
    Besse, T.
    Brendel, E.
    Loembe, B.
    Piccart, M.
    Hendlisz, A.
    ANNALS OF ONCOLOGY, 2007, 18 : 39 - 39
  • [22] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Kyriakos P. Papadopoulos
    Eytan Ben-Ami
    Amita Patnaik
    Denise Trone
    Jianke Li
    George D. Demetri
    BMC Cancer, 18
  • [23] Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors
    Bendell, Johanna C.
    Patel, Manish R.
    Moore, Kathleen N.
    Chua, Cynthia C.
    Arkenau, Hendrik-Tobias
    Dukart, Gary
    Harrow, Kim
    Liang, Chris
    ONCOLOGIST, 2019, 24 (04): : 455 - E121
  • [24] A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
    Eiji Kiyohara
    Atsushi Tanemura
    Kazuma Sakura
    Toshihiro Nakajima
    Akira Myoui
    Naoya Yamazaki
    Yoshio Kiyohara
    Ichiro Katayama
    Manabu Fujimoto
    Yasufumi Kaneda
    Cancer Immunology, Immunotherapy, 2022, 71 : 2041 - 2049
  • [25] TLK286: Phase I dose-escalation trial in patients with advanced malignancies.
    Rosen, LS
    Kadib, L
    Laxa, B
    Brown, J
    Kilfoil, G
    Gomez, R
    Wick, M
    Vollmer, C
    Brown, G
    CLINICAL CANCER RESEARCH, 2000, 6 : 4506S - 4506S
  • [26] Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial
    Papadopoulos, Kyriakos P.
    Ben-Ami, Eytan
    Patnaik, Amita
    Trone, Denise
    Li, Jianke
    Demetri, George D.
    BMC CANCER, 2018, 18
  • [27] A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma
    Kiyohara, Eiji
    Tanemura, Atsushi
    Sakura, Kazuma
    Nakajima, Toshihiro
    Myoui, Akira
    Yamazaki, Naoya
    Kiyohara, Yoshio
    Katayama, Ichiro
    Fujimoto, Manabu
    Kaneda, Yasufumi
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2022, 71 (08) : 2041 - 2049
  • [28] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
    Callahan, Margaret K.
    Kluger, Harriet
    Postow, Michael A.
    Segal, Neil H.
    Lesokhin, Alexander
    Atkins, Michael B.
    Kirkwood, John M.
    Krishnan, Suba
    Bhore, Rafia
    Horak, Christine
    Wolchok, Jedd D.
    Sznol, Mario
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +
  • [29] Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with relapsed/refractory ovarian cancer.
    Smit, WM
    Sufliarsky, J
    Spanik, S
    Wagnerová, M
    Kaye, S
    Oza, AM
    Gore, M
    Williams, K
    Johri, A
    Huinink, WWT
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 468S - 468S
  • [30] The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study
    Yonemori, Kan
    Shimizu, Toshio
    Kondo, Shunsuke
    Iwasa, Satoru
    Koyama, Takafumi
    Kitano, Shigehisa
    Sato, Jun
    Shimomura, Akihiko
    Shibaki, Ryota
    Suri, Ajit
    Kase, Yoichi
    Sumino, Shuuji
    Tamura, Kenji
    Yamamoto, Noboru
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (05) : 693 - 699
12345